decisionhealth Newsletters, Coder Pink Sheets - 2003 Issue 12 (December)
In-office drugs
Subscribe or sign in to view the full article.
Article Overview
This article explains a Medicare payment-policy issue affecting in-office drug administration, especially high-cost ophthalmology-related therapies. It discusses how proposed and changing reimbursement approaches may affect physician practices, billing practices, and patient notices, and it is relevant to coders, billing staff, and practice managers who work with Part B drugs and office-based procedures.
Why This Topic Matters
Payment methodology for office-administered drugs can materially affect practice revenue, patient billing workflows, and compliance. Understanding the policy context helps staff recognize why reimbursement may differ from charges and why certain patient-billing approaches are restricted.
Article Sections
-
Medicare drug payment changes
Overview of the policy changes being discussed for physician-office drug reimbursement and how they relate to Medicare payment methodology.
-
Impact on office-based ophthalmology practice
Discussion of how the reimbursement environment affects overhead, staffing, and the economics of office-based treatment in ophthalmology settings.
-
Patient billing and ABN considerations
General discussion of patient notification and billing constraints when a covered drug or supply is not fully reimbursed.
What You Will Learn
- The Medicare payment-policy context for in-office drugs
- Why reimbursement changes matter to physician practices
- How office billing and patient-notice issues can arise with covered drugs
- The operational impact of high-cost drug administration in specialty practices
Who Should Read This
- Medical coders
- Billing staff
- Practice managers
- Revenue cycle staff
- Ophthalmology office administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com